|
Cizzle Biotechnology Holdings PLC on Wednesday said the Canadian intellectual property office has granted protection to medical testing methods that use the CIZ1B lung cancer biomarker. Specifically, Canada has recognised IP claims for the ‘use of a fibrinogen capture agent to detect a CIZ1B variant’, Cizzle said. This test format was developed by the London-based life sciences company at the University of York. It is licensed to Cizzle Bio Inc in North America and the Caribbean, alongside having EU patent protection. Cizzle’s current focus is setting up partnerships with UK and European healthcare providers, including the NHS. ‘The company has a strong patent portfolio and continues to seek additional protection in other key markets globally,’ Cizzle noted on Wednesday. ‘In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course.’ Chief Scientific Officer Dawn Coverley said the patents ‘help to ensure that the company’s innovative and commercially scalable CIZ1B biomarker test will bring benefit to cancer patients, through the roll out of early detection programs.’ The company’s shares were up 21% at 1.70 pence on Wednesday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
